3,318 research outputs found

    Role of genetic research in the prevention of life-threatening rhythm and cardiac conduction disorders in young people

    Get PDF
    According to epidemiological studies, in Russia there is a tendency towards an increase in sudden cardiac death (SCD), including among young workingage people. The leading mechanism for SCD in young patients, including those with undifferentiated connective tissue disease, is recognized as rhythm and conduction disorders. At the same time, the most tragic cases are the first and only manifestation of SCD in children and young people without structural heart disease. The article presents a brief analysis of the genetic causes of life-threatening rhythm and conduction disorders in young people, as well as a generalization of the modern possibilities of a personalized diagnostic approach from the standpoint of early cardiovascular prevention. Timely genetic diagnosis of SCD risk makes it possible to identify a predisposition to the development of a fatal event long before its occurrence, which contributes to the timely implementation of preventive measures within a high cardiovascular risk strategy and secondary prevention, maintaining working capacity, creative and social activity of young patients, and improving the quality of life

    Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program

    Get PDF
    Aim. In practice, to evaluate the efficacy, safety and long-term adherence to therapy with a fixed-dose combination of ramipril/indapamide (Konsilar-D24) in patients with grade 1-2 hypertension (HTN) who have not achieved blood pressure (BP) control with prior therapy or have not taken antihypertensive therapy.Material and methods. This multicenter open-label observational program included 524 patients with grade 1-2 HTN who did not take antihypertensive therapy or did not reach the target BP level with mono or dual antihypertensive therapy, as well as patients shifted to Konsilar-D24 therapy no later than two weeks before the start of the program. All patients signed a written informed consent to participate in the program. The safety analysis set includes all patients who have taken at least one dose of a fixed-dose combination of ramipril/indapamide and have visited physician at least once during the program. The effectiveness analysis set included all patients in the safety population who completed the study in accordance with protocol (n=511). Clinical systolic blood pressure (SBP), diastolic BP (DBP) and heart rate were assessed at baseline, as well as at 0,5, 1, 3 and 6 months of treatment. A post hoc subgroup analysis of changes in BP and heart rate was performed depending on age, sex and baseline body mass index.Results. The fixed-dose combination of ramipril with indapamide significantly reduced SBP and DBP after 2-week treatment (-20,9Β±10,1 mm Hg; pConclusion. Despite the limitations inherent in observational studies, the KONSONANS program has demonstrated high efficacy and safety of fixed-dose combination of ramipril/indapamide taken once a day in hypertensive patients. Ramipril/indapamide fixed-dose combination therapy significantly improved BP control and achieved even lower individual target BP levels in the majority of hypertensive patients

    ΠŸΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Π΅ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ с дисплазиСй ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ: рСтроспСктивноС ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСскоС исслСдованиС

    Get PDF
    An analysis of medical documents and morphological examination of resected lung samples was done in 25 children had been operated for repeated pneumonias. All the children (100 %) were diagnosed undifferentiated connective tissue dysplasia (CTD) with marked clinical features. Morphological substrate of the repeated pneumonias was various defects of the lung growth. The results showed that the CTD as a genetic systemic pathology provided repeated pneumonias in structural abnormalities of the lungs. This fact should be taken into account in the diagnostic work-up.ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· мСдицинской Π΄ΠΎΠΊΡƒΠΌΠ΅Π½Ρ‚Π°Ρ†ΠΈΠΈ ΠΈ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² морфологичСского исслСдования Ρ€Π΅Π·Π΅Ρ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… участков Π»Π΅Π³ΠΊΠΈΡ… Ρƒ 25 Π΄Π΅Ρ‚Π΅ΠΉ, ΠΎΠΏΠ΅Ρ€ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρƒ ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ. Π£ 100% Π΄Π΅Ρ‚Π΅ΠΉ Π²ΠΎ врСмя осмотра диагностирована нСдиффСрСнцированная дисплазия ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ (Π”Π‘Π’) с Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½Ρ‹ΠΌΠΈ клиничСскими проявлСниями. ΠœΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ субстратом ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ явились Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Π΅ Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Ρ‹ ΠΏΠΎΡ€ΠΎΡ‡Π½ΠΎΠ³ΠΎ развития Π»Π΅Π³ΠΊΠΈΡ…. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ исслСдования ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΡŽΡ‚, Ρ‡Ρ‚ΠΎ Π”Π‘Π’ ΠΊΠ°ΠΊ гСнСтичСски Π΄Π΅Ρ‚Π΅Ρ€ΠΌΠΈΠ½ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ систСмный процСсс прСдрасполагаСт ΠΊ возникновСнию ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ Π½Π° Ρ„ΠΎΠ½Π΅ структурных Π°Π½ΠΎΠΌΠ°Π»ΠΈΠΉ Π»Π΅Π³ΠΊΠΈΡ…, Ρ‡Ρ‚ΠΎ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ ΡƒΡ‡ΠΈΡ‚Ρ‹Π²Π°Ρ‚ΡŒ Π² диагностичСском процСссС

    Π‘ΠΏΠΎΠ½Ρ‚Π°Π½Π½Ρ‹ΠΉ пнСвмоторакс ΠΈ дисплазия ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ: молСкулярно-гСнСтичСскиС исслСдования

    Get PDF
    Summary. To evaluate a role of polymorphic variants of alpha1-antitrypsin (AAT) genes and matrix metalloproteinase (MMP) genes for heritable susceptibility to bullous emphysema and primary spontaneous pneumothorax (PSP) in patients with connective tissue dysplasia (CTD), we analyzed polymorphic loci of PIZ (Glu342Lys), PIS (Glu264Val), MMP1 (1607insG), MMP9 (C-1562T), MMP12 (A-82G), and TIMP1 (Π‘536Π’) genes and studied serum AAT concentration. We did not find any significant difference between prevalence of the Z- and S-mutations of PI gene and serum AAT concentration between groups. MMP1 homozygous GG/GG genotype was associated with risk of PSP development (odds ratio (OR), 2.23; 95 % confidence interval (Π‘I): 1.34–3.73), MMP1 GG allele (OR, 2.27; 95 % CI: 1.61–3.20), MMP9 heterozigous Π‘/Π’ genotype (OR, 2.43; 95%CI: 1.37–4.31), MMP9 homozygous Π’/Π’ genotype (OR, 4.38; 95 % CI: 1.12–20.00), MMP9 T allele (OR, 2.78; 95 % CI: 1.74–4.46). All alleles and genotypes were found significantly more often in patients with signs of CTD. No statistically significant difference for any polymorphic locus of the studied genes was seen between prevalence of allele variants in patients with PSP but not having CTD and in population sample.РСзюмС. Π‘ Ρ†Π΅Π»ΡŒΡŽ ΠΎΡ†Π΅Π½ΠΊΠΈ Ρ€ΠΎΠ»ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½Ρ‹Ρ… Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠ² Π³Π΅Π½ΠΎΠ² Π°Π»ΡŒΡ„Π°1-антитрипсина (Ξ±1-АВ) ΠΈ матриксных ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ½Π°Π· (MMP) Π² Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ Π±ΡƒΠ»Π»Π΅Π·Π½ΠΎΠΉ эмфизСмы ΠΈ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ спонтанного пнСвмоторакса (БП) Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с дисплазиСй ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ (Π”Π‘Π’) ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½Ρ‹Ρ… локусов PIZ (Glu342Lys), PIS (Glu264Val), MMP1 (1607insG), MMP9 (C-1562T), MMP12 (A-82G), TIMP1 (Π‘536Π’) ΠΈ количСствСнноС ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Ξ±1-АВ Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ нСфСломСтричСским ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ. Π—Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ частоты Z- ΠΈ S-ΠΌΡƒΡ‚Π°Ρ†ΠΈΠΉ Π³Π΅Π½Π° PI ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ Ξ±1-АВ Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ ΠΌΠ΅ΠΆΠ΄Ρƒ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ выявлСно. Ассоциации с риском развития ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ БП выявлСны для Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡ‚Π½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° GG / GG Π³Π΅Π½Π° MMP1 (ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ риска (OΠ ) – 2,23, 95%-Π½Ρ‹ΠΉ Π΄ΠΎΠ²Π΅Ρ€ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ ΠΈΠ½Ρ‚Π΅Ρ€Π²Π°Π» (Π”Π˜) – 1,34–3,73), аллСля GG Π³Π΅Π½Π° MMP1 (OΠ  – 2,27, 95%-Π½Ρ‹ΠΉ Π”Π˜ – 1,61–3,20), Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ·ΠΈΠ³ΠΎΡ‚Π½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° Π‘ / Π’ Π³Π΅Π½Π° MMP9 (OΠ  – 2,43, 95%-Π½Ρ‹ΠΉ Π”Π˜ – 1,37–4,31), Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡ‚Π½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° Π’ / Π’ Π³Π΅Π½Π° MMP9 (OΠ  – 4,38, 95%-Π½Ρ‹ΠΉ Π”Π˜ – 1,12–20,00), аллСля Π’ Π³Π΅Π½Π° MMP9 (OΠ  – 2,78, 95%-Π½Ρ‹ΠΉ Π”Π˜ – 1,74–4,46). ВсС Π²Ρ‹ΡˆΠ΅ΠΏΠ΅Ρ€Π΅Ρ‡ΠΈΡΠ»Π΅Π½Π½Ρ‹Π΅ Π°Π»Π»Π΅Π»ΠΈ ΠΈ Π³Π΅Π½ΠΎΡ‚ΠΈΠΏΡ‹ достовСрно Ρ‡Π°Ρ‰Π΅ Π²ΡΡ‚Ρ€Π΅Ρ‡Π°Π»ΠΈΡΡŒ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ Π”Π‘Π’. БтатистичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρƒ частотой Π°Π»Π»Π΅Π»ΡŒΠ½Ρ‹Ρ… Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠ² Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹ΠΌ БП, Π½Π΅ ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΡ… ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΎΠ² Π”Π‘Π’, ΠΈ популяционной Π²Ρ‹Π±ΠΎΡ€ΠΊΠΎΠΉ Π½Π΅ Π±Ρ‹Π»ΠΎ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΎ Π½ΠΈ для ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½ΠΎΠ³ΠΎ локуса ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΡ‹Ρ… Π³Π΅Π½ΠΎΠ²

    Hunt for new phenomena using large jet multiplicities and missing transverse momentum with ATLAS in 4.7 fbβˆ’1 of s√=7TeV proton-proton collisions

    Get PDF
    Results are presented of a search for new particles decaying to large numbers of jets in association with missing transverse momentum, using 4.7 fbβˆ’1 of pp collision data at s√=7TeV collected by the ATLAS experiment at the Large Hadron Collider in 2011. The event selection requires missing transverse momentum, no isolated electrons or muons, and from β‰₯6 to β‰₯9 jets. No evidence is found for physics beyond the Standard Model. The results are interpreted in the context of a MSUGRA/CMSSM supersymmetric model, where, for large universal scalar mass m 0, gluino masses smaller than 840 GeV are excluded at the 95% confidence level, extending previously published limits. Within a simplified model containing only a gluino octet and a neutralino, gluino masses smaller than 870 GeV are similarly excluded for neutralino masses below 100 GeV
    • …
    corecore